olmutinib   Click here for help

GtoPdb Ligand ID: 9196

Synonyms: BI-1482694 | Example 1 [US20130116213] | HM-61713 | HM61713
Approved drug
olmutinib is an approved drug (South Korea (2016))
Compound class: Synthetic organic
Comment: Olmutinib from Hanmi Pharmaceutical, approved in South Korea for lung cancer, targets mutant epidermal growth factor receptor (EGFR) selectively over wild-type. It is reported as an oral, third-generation EGFR tyrosine kinase inhibitor (binding covalently), however there is no published, peer-reviewed data to confirm this. The potential for using third-generation EGFR inhibitors in EGFR-mutated non-small lung cancer is reviewed by Russo et al. (2017) [7]. Olmutinib is claimed in patent WO2011162515 [1]. Full text descriptions and structure images are available in US20130116213 [3], where it is identified as Example 1 (N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide). Note we updated this entry in Nov 2016 with the removal of the incorrect synonyms HM-71224 and LY3337641 which refer to a blinded Hanmi BTK inhibitor [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 110.86
Molecular weight 486.18
XLogP 4.26
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES C=CC(=O)Nc1cccc(c1)Oc1nc(Nc2ccc(cc2)N2CCN(CC2)C)nc2c1scc2
Isomeric SMILES C=CC(=O)Nc1cccc(c1)Oc1nc(Nc2ccc(cc2)N2CCN(CC2)C)nc2c1scc2
InChI InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
1. Cha MY, Ha TH, Jeon JY, Jo MG, Kang SJ, Kim MS, Kim MR, Kwak EJ, Lee JY, Lee KO, Suh KH. (2012)
Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity.
Patent number: WO2011162515. Assignee: Hanmi Holdings Co. , Ltd.. Priority date: 30/06/2010. Publication date: 03/05/2012.
2. Kim ES. (2016)
Olmutinib: First Global Approval.
Drugs, 76 (11): 1153-7. [PMID:27357069]
3. MY Cha, Kang SJ, Kim MR, Lee JY, Jeon JY, Jo MG, Kwak EJ, Lee KO, Ha TH, Suh KH, Kim MS. (2013)
Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity.
Patent number: US20130116213. Assignee: Hanmi Science Co., Ltd.. Priority date: 23/06/2010. Publication date: 09/05/2013.
4. Park JK, Byun JY, Park JA, Kim YY, Lee YJ, Oh JI, Jang SY, Kim YH, Song YW, Son J et al.. (2015)
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Arthritis Res Ther, 18: 91. [PMID:27090981]
5. Park K, Han JY, Kim DW, Bazhenova LA, Ou SH, Pang YK, Hin HS, Juan O, Son J, Jänne P. (2016)
190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).
J Thorac Oncol, 11 (4 Suppl): S139. [PMID:27198328]
6. Park K, Lee JS, Han JY, Lee KH, Kim JH, Cho EK, Cho JY, Min YJ, Kim JS, Kim DW. (2016)
1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose.
J Thorac Oncol, 11 (4 Suppl): S113. [PMID:27198272]
7. Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghì M, Rolfo C, Adamo V. (2017)
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.
Crit Rev Oncol Hematol, 117: 38-47. [PMID:28807234]